88
7
1
3
1
Cat. No. | Product Name | ||
---|---|---|---|
L2170 | 肿瘤免疫治疗小分子化合物库 | 449 compounds | |
449 种靶向肿瘤免疫治疗靶点的小分子,可用于高通量和高内涵筛选,是研究肿瘤免疫治疗的有力工具; |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6400 |
AZD3514
|
Androgen Receptor | Endocrinology/Hormones |
AZD3514 是一种口服雄激素受体下调剂(Ki :2.2 μM),能够减少 AR 蛋白表达。 | |||
T6207 |
SC144
|
Apoptosis; Interleukin | Apoptosis; Immunology/Inflammation |
SC144 是一种口服活性 gp130 抑制剂。它结合 gp130,诱导 gp130 磷酸化(S782) 和去糖基化,消除 Stat3 磷酸化和核易位,进一步抑制下游靶基因的表达。它对 gp130 配体触发的信号转导有明显的抑制作用,可诱导人卵巢癌细胞凋亡。 | |||
T10717 |
Inobrodib
CBP-IN-1 |
Epigenetic Reader Domain | Chromatin/Epigenetic |
Inobrodib (CBP-IN-1) 是一种口服活性的强选择性p300/CBP 抑制剂,与 p300 和 CBP 结合,Kd 值为 1.3 和 1.7 nM。它抑制前列腺癌细胞系的细胞增殖并降低雄激素受体和 C-MYC 调节的基因表达。 | |||
T5414 |
Glumetinib
SCC244 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Glumetinib (SCC244) 是一种高选择性、ATP 竞争性的、口服具有活力的 c-Met 抑制剂。它对 c-Met 的选择性超过 312 种激酶,包括 c-Met 家族成员 RON 和高度同源的激酶 Axl、Mer、TyrO3。它具有抗肿瘤作用。 | |||
T0152 |
Bosutinib
伯舒替尼,SKI-606 |
Bcr-Abl; Src; Autophagy | Angiogenesis; Autophagy; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Bosutinib (SKI-606) 是一种合成的喹诺酮衍生物和双激酶抑制剂,靶向 Abl 和 Src 激酶的 IC50分别为 1 nM 和 1.2 nM。 | |||
T4337 |
PCI 29732
PCI29732,PCI-29732 |
Others; BCRP; BTK | Angiogenesis; Membrane transporter/Ion channel; Others; Tyrosine Kinase/Adaptors |
PCI 29732 是一种有效的可逆BTK 抑制剂,对 BTK、Lck 和 Lyn 的Kiapp 值分别为 8.2、4.6 和 2.5 nM。它通过竞争性结合ABCG2 的 ATP 结合位点来抑制ABCG2的功能。 | |||
T1756L |
Ilaprazole
IY81149,艾普拉唑,IY 81149,IY-81149 |
Proton pump; TOPK | MAPK; Membrane transporter/Ion channel |
Ilaprazole (IY-81149) 是一种具有口服活性质子泵抑制剂,以剂量依赖性方式不可逆地抑制H+/K+-ATPase,在兔壁细胞制剂中的IC50为 6 μM。它也是一种有效的T 细胞起源蛋白激酶(TOPK)抑制剂,用于胃溃疡的研究。 | |||
T12493 |
PK68
|
Others; RIP kinase | Apoptosis; NF-κB; Others |
PK68 是 II 型受体相互作用激酶 1 (RIPK1, IC50 = 90 nM) 的有效特异性抑制剂。 PK68可用于治疗炎症性疾病和癌症转移的研究。 | |||
T39710 |
ARV-471
Vepdegestrant |
Estrogen Receptor/ERR; PROTACs | Endocrinology/Hormones; PROTAC |
ARV-471 (Vepdegestrant) 是一种高效的,口服有效的基于 Cereblon 配体的雌激素受体降解剂 PROTAC 。ARV-471 常用于研究乳腺癌。 | |||
T21412 |
Ketorolac
Toradol,Sprix,Acuvail,Macril,酮咯酸,Acular |
COX | Immunology/Inflammation; Neuroscience |
Ketorolac (Acuvail) 是非甾体抗炎剂,是非选择性的COX 抑制剂,对 COX-1 和 COX-2 的IC50值分别为 20 和 120 nM。 | |||
T1756 |
Ilaprazole sodium
IY-81149 sodium,艾普拉唑钠 |
Proton pump; TOPK | MAPK; Membrane transporter/Ion channel |
Ilaprazole sodium (IY-81149 sodium) 是一种具有口服活性质子泵抑制剂,以剂量依赖性方式不可逆地抑制 H+/K+-ATPase,在兔壁细胞制剂中的 IC50为 6 μM。它也是一种有效的 T 细胞起源蛋白激酶(TOPK)抑制剂,用于胃溃疡的研究。 | |||
T5462 |
Almonertinib
HS-10296,阿美替尼 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Almonertinib (HS-10296) 是EGFR 激活突变抑制剂和EGFR T790M 耐受突变抑制剂,对 EGFR 致敏和 T790M 耐药突变具有高选择性,用于非小细胞肺癌的研究。它对 T790M、T790M/L858R 和 T790M/Del19 表现出较强的抑制活性,对野生型的抑制作用较弱。 | |||
T7535 |
RGX-202
胍基丙酸,β-GPA,3-Guanidinopropionic Acid |
AMPK; PPAR | Chromatin/Epigenetic; DNA Damage/DNA Repair; Metabolism; PI3K/Akt/mTOR signaling |
RGX-202 (β-GPA) 是口服有活性的SLC6A8转运蛋白抑制剂。它在体内外均能够强烈地抑制肌酸输入,降低细胞内磷酸肌酸和 ATP 水平,诱导肿瘤凋亡,可于研究肿瘤。 | |||
T0459 |
Sulindac
Arthrocine,MK-231,舒林酸,Clinoril,Sulindac sulfoxide |
COX; Autophagy | Autophagy; Immunology/Inflammation; Neuroscience |
Sulindac (Sulindac sulfoxide) 是一种非甾体类抗炎剂,可抑制COX-2的活性,也可抑制 COX-2 的过表达。它是一种亚磺酰基茚衍生物前药,具有潜在的抗肿瘤活性。 | |||
T6763 |
Xevinapant
ARRY-334543,SM-406,AT406,Debio-1143 |
IAP | Apoptosis |
Xevinapant (Debio-1143) 是一种有效的 Smac 模拟物和 IAP 的拮抗剂,能够抑制 XIAP,cIAP1 和 cIAP2 蛋白,Ki 值分别为 66.4,1.9 和 5.1 nM。 | |||
T1952 |
MK-2206 dihydrochloride
MK-2206 2HCl |
Apoptosis; Akt; Autophagy | Apoptosis; Autophagy; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling |
MK-2206 dihydrochloride (MK-2206 2HCl) 是一种变构 Akt 抑制剂,抑制 Akt1、Akt2 和 Akt3 (IC50=8/12/65 nM),具有口服活性的、高效选择性。MK-2206 dihydrochloride 具有抗肿瘤活性。 | |||
T12574 |
PTC299
Emvododstat,(4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate |
VEGFR; Dehydrogenase | Angiogenesis; Metabolism; Tyrosine Kinase/Adaptors |
PTC299 ((4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate) 是一种口服活性的 VEGFA mRNA 翻译抑制剂,可选择性地抑制转录后水平的 VEGF 蛋白合成。它还是二氢乳酸脱氢酶 (DHODH) 的有效抑制剂,可研究血液系统恶性肿瘤。 | |||
T14511 |
BAY1082439
N-[8-[[(2R)-2-羟基-3-(吗啉-4-基)丙基]氧基]-7-甲氧基-2,3-二氢咪唑并[1,2-C]喹唑啉-5-基]-2-甲基吡啶-3-甲酰胺 |
Apoptosis; PI3K | Apoptosis; PI3K/Akt/mTOR signaling |
BAY1082439 是一种具有口服活性的,选择性 PI3Kα/β/δ抑制剂。它也能抑制 PIK3CA 的突变形式,它对抑制 Pten 丢失的前列腺癌的生长有很强的作用。 | |||
T36573 |
NHWD-870
|
Apoptosis; Epigenetic Reader Domain | Apoptosis; Chromatin/Epigenetic |
NHWD-870 是一种有效且特异性的 BET 家族溴结构域抑制剂,仅与 BRD2、BRD3、BRD4 (IC50 = 2.7 nM) 和 BRDT 结合。 NHWD-870 具有强大的抗肿瘤功效,并通过增加肿瘤细胞凋亡和抑制肿瘤增殖来抑制癌细胞-巨噬细胞相互作用。 | |||
T16492 |
PF-06459988
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
PF-06459988 是一种新型的的、有效的、具有口服活性的、不可逆的和选择性的表皮生长因子受体( EGFR) 突变体抑制剂。PF-06459988 对含 T790M 的 EGFRs 双突变体具有高效性和高亲和力,对 WT EGFR 具有极小的活性。PF-06459988 使治疗癌症的候选药物。 | |||
T3299 |
Xevinapant hydrochloride
AT-406 HCl,SM-406 |
Apoptosis; IAP | Apoptosis |
Xevinapant hydrochloride (AT-406 HCl) 是口服生物可利用的 Smac 模拟物,也是细胞凋亡蛋白抑制剂的拮抗剂。它在无细胞功能测定中有效拮抗 XIAP BIR3 蛋白,诱导细胞 cIAP1 蛋白的快速降解,并抑制各种人类癌细胞系中的癌细胞生长。它在诱导异种移植肿瘤细胞凋亡方面非常有效。 | |||
T5675 |
Almonertinib hydrochloride
HS-10296 hydrochloride,盐酸阿美替尼 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Almonertinib hydrochloride (HS-10296 hydrochloride) 是一种 EGFR 激活突变和 T790M 耐药突变的小分子抑制剂,用于非小细胞肺癌的研究,对 T790M、T790M/L858R 和 T790M/Del19 表现出较强的抑制活性,对野生型的抑制作用较弱。 | |||
T67875 |
DHODH-IN-23
|
Dehydrogenase | Metabolism |
DHODH-IN-23是一种 DHODH 抑制剂,具有口服活性。DHODH-IN-23常用于对癌症的研究。 | |||
T36802L |
Bisubstrate Inhibitor 78 HCl
Bisubstrate Inhibitor 78 HCl(2368247-39-4 Free base) |
Others | Others |
Bisubstrate Inhibitor 78 HCl 是一种 NNMT 抑制剂(IC50 = 1.41 μM),具有潜在的抗癌活性,在 100μM 时抑制HSC-2口腔癌细胞增殖。 | |||
T6883 |
Samotolisib
GTPL8918,LY3023414 |
DNA-PK; PI3K; mTOR; Autophagy | Autophagy; DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
Samotolisib (LY3023414) 在低纳摩尔浓度下,有效抑制mTORC1/2。它选择性地有效抑制PI3Kα、PI3Kβ、PI3Kδ、PI3Kγ、DNA-PK 和mTOR,IC50分别为 6.07 nM、77.6 nM、38 nM、23.8 nM、4.24 nM 和 165 nM。它可用于多种肿瘤和癌症的试验。 | |||
T16549 |
PKI-166
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
PKI-166是一种可口服的EGF-R 酪氨酸激酶抑制剂(IC50 : 0.7 nM),具有有效性和选择性。PKI-166能有效抑制包括胰腺癌在内的多种人类癌细胞的生长和转移。 | |||
T61318 |
BRD4 Inhibitor-20
|
Epigenetic Reader Domain | Chromatin/Epigenetic |
BRD4 Inhibitor-20是一种有效的溴结构域蛋白4(BRD4)抑制剂,具有口服活性。BRD4 Inhibitor-20在癌细胞系中具有抗增殖活性,并被用于各种癌症的研究,如结肠癌。 | |||
T67872 |
VT104
|
YAP | Stem Cells |
VT104是一种有效的YAP/TAZ 抑制剂,具有口服活性,可用于癌症研究。VT104阻止内源性TEAD1和TEAD3蛋白棕榈酰化。 | |||
T22263 |
Bavdegalutamide
ARV-110 |
Androgen Receptor | Endocrinology/Hormones |
Bavdegalutamide (ARV-110) 是一种雄激素受体 (AR) 的 PROTAC 降解剂。 Bavdegalutamide 可用于前列腺癌的研究。 Bavdegalutamide 具有口服活性和选择性,并促进 AR 的泛素化和降解。 | |||
T1920 |
Capivasertib
AZD5363 |
Akt; PKA; mTOR; Autophagy | Autophagy; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
Capivasertib (AZD5363) 是一种广谱的 AKT 抑制剂,对 Akt1、Akt2 和 Akt3 均有抑制活性 (IC50=3/7/7 nM),具有口服活性。Capivasertib 具有抗肿瘤活性,可以用于治疗乳腺癌。 | |||
T0078 |
Lapatinib
GSK572016,GW572016,拉帕替尼 |
EGFR; Ferroptosis; Autophagy | Angiogenesis; Apoptosis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Lapatinib (GW572016) 是一种 ErbB2 和 EGFR 的抑制剂 (IC50=9.2/10.8 nM),具有口服活性。Lapatinib 具有抗肿瘤活性,可以用于治疗 HER2 过表达的晚期或转移性乳腺癌。 | |||
T12906 |
SI-2 hydrochloride
EPH 116 hydrochloride |
Src | Angiogenesis; Tyrosine Kinase/Adaptors |
SI-2 hydrochloride (EPH 116 hydrochloride) 是 SRC-3 的抑制剂,诱导乳腺癌细胞死亡的 IC50 值为 3-20 nM。SI-2 hydrochloride 具有良好的药代动力学特征和改善的毒性,以及可接受的口服可用性。 | |||
T4420 |
4-Hydroxytamoxifen
ICI 79280,(Z)-4-hydroxy Tamoxifen,4-羟基他莫昔芬,trans-4-Hydroxytamoxifen |
Estrogen Receptor/ERR; Estrogen/progestogen Receptor | Endocrinology/Hormones |
4-Hydroxytamoxifen (ICI 79280) 是 Tamoxifen 的活性代谢产物,是一种雌激素受体调节剂 (SERM),具有选择性和口服有效性。4-Hydroxytamoxifen 具有抗肿瘤活性,可用于乳腺癌的研究。 | |||
T5993 |
ARN-3236
|
AMPK; SIK | Chromatin/Epigenetic; PI3K/Akt/mTOR signaling |
ARN-3236 是一种口服有活性的、具有选择性的盐诱导激酶2 (SIK2)抑制剂,它能够抑制SIK1 (IC50:21.63 nM)、SIK2(IC50<1 nM)和 SIK3(IC50:6.63 nM)。它具有抗肿瘤作用。 | |||
T10895 |
CSN5i-3
|
Apoptosis; Others | Apoptosis; Others |
CSN5i-3 是一种新型有效口服且具有选择性的 CSN5/Jab1 抑制剂,抑制 CSN 催化的 Cul1 deneddylation IC50 值为 5.8 nM。CSN5i-3具有抗癌活性,抑制细胞增殖并诱导人乳腺癌细胞凋亡。 | |||
T2490 |
Osimertinib
AZD-9291,Mereletinib,奥希替尼 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Osimertinib (AZD-9291) 是一种 EGFR 三代抑制剂,抑制二代 EGFR 抑制剂产生的 T790M 耐药突变,具有不可逆性和口服活性。Osimertinib 具有抗肿瘤活性,用于治疗 EGFR 突变的非小细胞肺癌。 | |||
T19671 |
AZ31
AZ 31,AZ-31 |
ATM/ATR | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
AZ31 是一种 ATM 抑制剂,具有有效性、高选择性、和口服活性。AZ31对 ATM 酶、细胞内 ATM 具有抑制作用,IC50 值 分别为<1.2 nM 和 46 nM。AZ31 表现出优异的 ATR 选择性 、PIKK 家族选择性和泛激酶选择性。AZ31 是一种强效的体外放射增敏剂,可用于研究癌症。 | |||
T2078 |
Fimepinostat
CUDC-907,PI3K/HDAC Inhibitor,CUDC 907 |
Apoptosis; PI3K; HDAC | Apoptosis; Chromatin/Epigenetic; DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
Fimepinostat (CUDC 907) 是一种 I 型PI3K 及 I 和 II 型HDAC 酶抑制剂,作用于 PI3Kα/PI3Kβ/PI3Kδ 和 HDAC1/HDAC2/HDAC3/HDAC10 ,IC50分别为 19/54/39 nM 和 1.7/5.0/1.8/2.8 nM。 | |||
T40565 |
5MPN
|
Others | Others |
5MPN is a novel compound that functions as a highly potent and selective inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4). This compound demonstrates oral activity and serves as a first-in-class inhibitor. Through competitive inhibition of the F6P binding site, 5MPN effectively hinders the functionality of PFKFB4, with a Ki value of 8.6 μM. Importantly, it exhibits no inhibitory effects on PFK-1 or PFKFB3. By specifically targeting the sugar metabolism of tumors, 5MPN... | |||
T19710 |
Ciglitazone
Ciglitazona,U 63287,ADD3878,ADD-3878,U-63287,ADD 3878 |
Apoptosis; p38 MAPK; PPAR | Apoptosis; DNA Damage/DNA Repair; MAPK; Metabolism |
Ciglitazone (ADD 3878) 是一种强效和选择性的PPARγ激动剂(EC50:3μM)和口服降糖药。Ciglitazone 抑制th17细胞的增殖和分化,降低胰岛素水平、血管内皮生长因子的产生和血压,诱导胃癌细胞的细胞周期停止。Ciglitazone 能诱导负鼠肾上皮细胞的凋亡,激活p38 MAPK 和凋亡诱导因子(AIF)的核转位。 Ciglitazone 在肥胖症和高血糖症的动物模型中表现出降血糖活性。 | |||
T10898 |
Samuraciclib hydrochloride
ICEC0942 hydrochloride,CT7001 hydrochloride |
Apoptosis; CDK | Apoptosis; Cell Cycle/Checkpoint |
Samuraciclib hydrochloride (ICEC0942 hydrochloride) 是一种具有选择性,ATP 竞争性和口服活性的CDK7抑制剂,IC50为 41 nM。它以 GI50值为 0.2-0.3 µM 来抑制乳腺癌细胞系的生长,具有抗肿瘤作用。 | |||
T9972 |
Divarasib
GDC-6036 |
Ras | GPCR/G Protein; MAPK |
Divarasib (GDC-6036) (GDC-6036)是一种正在研究的、口服的、高效力和选择性的 KRAS G12C 抑制剂,IC50 为 <0.01 μM。Divarasib 不可逆地将 KRAS G12C 癌蛋白锁定在非活性状态,抑制肿瘤细胞生长。它正在被研究用于实体肿瘤,包括非小细胞肺癌和结肠直肠癌及其他类型的癌症。 | |||
T3716 |
Rolapitant
罗拉吡坦,SCH619734,罗拉匹坦 |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Rolapitant (SCH619734) 是一种高效选择性具有口服活性的神经激肽 1 受体抑制剂,Ki 值为0.66 nM。 | |||
T2325 |
Neratinib
HKI-272,来那替尼 |
EGFR; HER | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Neratinib (HKI-272) 是一种酪氨酸激酶受体抑制剂,可以抑制 HER2 和 EGFR (IC50=59/92 nM),具有不可逆性和口服活性。Neratinib 具有抗肿瘤活性,可以用于治疗乳腺癌。 | |||
T19779 |
SL-01
Z L Phe chloromethyl ketone,NSC-251810,ZLPhe chloromethyl ketone,Z-Phe-chloromethylketone |
Others | Others |
SL-01 is an oral derivative of gemcitabine. SL-01 inhibited human breast cancer growth through the induction of apoptosis. SL-01 inhibited human cancer growth more potently than gemcitabine. | |||
T25350 |
DPQZ
|
Others | Others |
DPQZ is an anti-tubulin compound acting by inducing cell apoptosis in human oral cancer cells through Ras/Raf inhibition and MAP kinases activation. | |||
T18652 |
RTC-30
|
Others | Others |
RTC-30 is an optimized phenothiazine compound possessing potent anti-cancer properties. It is formulated with a hydroxylated linker (N) which enhances its oral bioavailability[1]. | |||
T31936 |
GLL398
GLL 398,GLL-398 |
Others | Others |
GLL398 is an oral selective estrogen receptor down-regulating agent that strongly binds to ERα (IC50 =1.14 nM) and effectively degrades ERα in MCF-7 breast cancer cells (IC50 = 0.21 μM). | |||
T38050 |
CP-609754
|
Transferase | Metabolism |
CP-609754 是高效的、可逆的法尼基转移酶抑制剂,对重组人 H-Ras 和重组 K-Ras 法尼基化的 IC50分别为 0.57 ng/mL 和 46 ng/mL。CP-609754有潜在的抗癌作用。 | |||
T61479 |
LOX-IN-3 dihydrochloride monohydrate
|
Others | Others |
LOX-IN-3 dihydrochloride monohydrate (Compound 33) is a lysyl oxidase (LOX) inhibitor with oral activity. It is specifically designed for research purposes in the areas of fibrosis, cancer, and angiogenesis [1]. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2S1797 |
Santalol
檀香醇;白檀油萜醇;檀香脑,檀香醇 |
Antioxidant; Antifungal | Microbiology/Virology; oxidation-reduction |
Santalol 是一种檀香醇的 α 和 β-异构体混合物。 其中α-santalol 分离自檀香油中,是一种有前途的抗癌药,能够预防口腔癌、前列腺癌、乳腺癌和皮肤癌。 | |||
T4S0797 |
Berberine
小檗碱,Berberin,Umbellatine,黄连素 |
Reactive Oxygen Species; Topoisomerase; Endogenous Metabolite; Antibacterial; Antibiotic; Autophagy | Autophagy; DNA Damage/DNA Repair; Immunology/Inflammation; Metabolism; Microbiology/Virology; NF-κB |
Berberine (Umbellatine) 属于生物碱类天然产物,可以激活 AMPK、抑制 DNA 拓扑异构酶、诱导 ROS 生成。Berberine 具有抗肿瘤、抗菌、降血糖、降血脂等生物学活性。 | |||
TN2738 |
2,6-Dimethoxy-1-acetonylquinol
|
Antifection | Microbiology/Virology |
2,6-Dimethoxy-1-acetonylquinol shows varying degrees of in vitro antimalarial activity against Plasmodium falciparum. It is devoid of significant cytotoxicity to the human oral epidermoid KB cancer cell line. | |||
TN3812 |
Dehydrovomifoliol
|
AChR | Neuroscience |
Dehydrovomifoliol could be a marker of Polish heather honey. Dehydrovomifoliol exhibits moderate acetylcholinesterase (AChE) inhibitory activities. Dehydrovomifoliol shows significant cytotoxic activities against three human cancer cell lines, namely, HONE-1 nasopharyngeal, KB oral epidermoid carcinoma, and HT29 colorectal carcinoma cells, and the IC(50) values in the range 3.7-8.1 microM. | |||
T81951 |
Lanosta-7,9(11),24-trien-3α-hydroxy-26-oic acid
|
||
Lanosta-7,9(11),24-trien-3α-hydroxy-26-oic acid,亦称为灵芝酸24,展现了强大的细胞毒性能,能够抑制多种癌细胞株的增殖,包括人肺癌细胞CH27、黑色素瘤细胞M21和口腔癌细胞HSC-3。 | |||
TN4194 |
Heliangin
|
IL Receptor; TNF; NF-κB; MAPK; Prostaglandin Receptor | Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK; NF-κB |
Heliangin shows anti-inflammatory effects, it can inhibit lipopolysaccharide-induced inflammation through signaling NF-κB pathway on LPS-induced RAW 264.7 cells. Heliangin has anti-cancer activity, it exhibits cytotoxicity against human oral epidermoid ( | |||
T36845 |
Isogarcinol
|
Others | Others |
Isogarcinol is a natural polyisoprenylated benzophenone first isolated from plant species in the genus Garcinia. It has immunosuppressant actions, inhibiting the protein phosphatase calcineurin (IC50 = 36 μM) and suppressing the proliferation of T cells. Oral administration of isogarcinol in mice decreases delayed type hypersensitivity, prolongs graft survival in allogeneic skin transplants, suppresses inflammation in collagen-induced arthritis, and reduces clinical symptoms in experimental auto... |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPJ-00157 |
CD82 Protein, Human, Recombinant (hFc)
Tetraspanin-27,KAI1,ST6,TSPAN27,TSPAN274F9,CD82 molecule,Tsp... |
Human | HEK293 Cells |
CD82 antigen, also known as Kai-1, is a widely expressed palmitoylated molecule of the tetraspanin superfamily. KAI1/CD82 is localized on cell membrane and form interactions with other tetraspanins, integrins and chemokines which are respectively responsible for cell migration, adhesion and signaling. CD82/Kai-1 is a component of the promiscuous TIMP-1 interacting protein complex on the cell surface of human adenocarcinoma cells and gives insight into tumorigenic metastatic potential. CD82/Kai-1... | |||
TMPJ-00160 |
EMMPRIN/CD147 Protein, Human, Recombinant (His)
5F7,TCSF,OK Blood Group Antigen,Tumor Cell-Derived Collagena... |
Human | HEK293 Cells |
Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) belongs to the immunoglobulin superfamily, which has the homology to both the immunoglobulin V domain and MHC class II antigen β-chain. EMMPRIN is a transmembrane glycoprotein with different forms, resulting from different modes of glycosylation and N-terminal sequence variants. EMMPRIN can be expressed in breast cancer, oral squamous cell carcinoma, glioma, lymphoma, lung, bladder, and melanoma carcinomas cells. EMMPRIN promotes invasion,... | |||
TMPY-02220 |
HRAS Protein, Human, Recombinant (His)
HAMSV,Harvey rat sarcoma viral oncogene homolog,C-H-RAS,C-HA... |
Human | Baculovirus Insect Cells |
HRas, also known as HRAS, belongs to the small GTPase superfamily, Ras family, and is widely expressed. It functions in signal transduction pathways. HRas can bind GTP and GDP, and they have intrinsic GTPase activity. It undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS). FCSS is a rare condition characterized by prenatally increase... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T11067 |
VX-984
M9831 |
DNA-PK | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
VX-984 (M9831) 是一种可口服的、具有选择性的的、可透过血脑屏障的 DNA-PK 抑制剂。VX-984 对非同源性末端 NHEJ 的接合具有抑制作用,可作用于 DSBs 使 DNA 双链断裂。VX-984常见于对胶质母细胞瘤 (GBM) 和非小细胞肺癌 (NSC-LC) 的研究。 |